Evaluation of Glycemic Control and Predictors of Severe Illness and Death in Patients With Diabetes Hospitalized With COVID-19
Journal of Community Hospital Internal Medicine Perspectives, doi:10.55729/2000-9666.1127
Objectives: To identify risk factors for severe disease and death among patients with diabetes and coronavirus disease 2019 (COVID-19) infection. Methods: This retrospective cohort study conducted at three hospitals included 733 consecutive patients with DM admitted with confirmed COVID-19 (March 1 -December 31, 2020). Multivariable logistic regression was performed to identify predictors of severe disease and death. Results: The mean age was 67.4 ± 14.3 years, 46.9% were males and 61.5% were African American. Among all patients, 116 (15.8%) died in the hospital. A total of 317 (43.2%) patients developed severe disease, 183 (25%) were admitted to an ICU and 118 (16.1%) required invasive mechanical ventilation. Increasing BMI (OR, 1.13; 95% CI, 1.02e1.25), history of chronic lung disease (OR, 1.49; 95% CI, 1.05e2.10) and increasing time since the last HbA1c test (OR, 1.25; 95% CI, 1.05e1.49) were the preadmission factors associated with increased odds of severe disease. Preadmission use of metformin (OR, 0.67; 95% CI, 0.47e0.95) or GLP-1 agonists (OR, 0.49; 95% CI, 0.27e0.87) was associated with decreased odds of severe disease. Increasing age (OR, 1.21; 95% CI, 1.09e1.34), co-existing chronic kidney disease greater than stage 3 (OR, 3.38; 95% CI, 1.67e6.84), ICU admission (OR, 2.93; 95% CI, 1.28e6.69) and use of invasive mechanical ventilation (OR, 8.67, 95% CI, 3.88e19.39) were independently associated with greater odds of in-hospital death. Conclusion: Several clinical characteristics were identified to be predictive of severe disease and in-hospital death among patients with underlying diabetes hospitalized with COVID-19.
Author contributions J.M.: data collection, data analysis, writing e original draft; N.P.: data collection, writing e original draft; M.T., S.J., J.L. and S.A.: data collection, writing e review & editing; A.T.: conceptualization, supervision, writing -review & editing. All authors read and approved the final manuscript.
Conflict of interest The authors declare that they have no competing or conflicts of interests.
Agarwal, Schechter, Southern, Crandall, Tomer, Preadmission diabetes-specific risk factors for mortality in hospitalized patients with diabetes and coronavirus disease 2019, Diabetes Care, doi:10.2337/dc20-1543
Aleem, Samad, Slenker, Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19)
Apicella, Campopiano, Mantuano, Mazoni, Coppelli et al., COVID-19 in people with diabetes: understanding the reasons for worse outcomes, Lancet Diabetes Endocrinol, doi:10.1016/S2213-8587(20)30238-2
Bai, Lian, Li, Zhang, Qiao, The active GLP-1 analogue liraglutide alleviates H9N2 influenza virus-induced acute lung injury in mice, Microb Pathog, doi:10.1016/j.micpath.2020.104645
Bello-Chavolla, Bahena, Opez, Ne, Predicting mortality due to SARS-CoV-2: a mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico, J Clin Endocrinol Metab, doi:10.1210/clinem/dgaa346
Bode, Garrett, Messler, Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States, J Diabetes Sci Technol, doi:10.1177/1932296820924469
Buuren S Van, Groothuis-Oudshoorn, Mice: multivariate imputation by chained equations in R, J Stat Software, doi:10.18637/jss.v045.i03
Cariou, Hadjadj, Wargny, Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study, Diabetologia, doi:10.1007/s00125-020-05180-x
Hariyanto, Intan, Hananto, Putri, Kurniawan, Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): a systematic review, meta-analysis, and metaregression, Diabetes Res Clin Pract, doi:10.1016/j.diabres.2021.109031
Izcovich, Ragusa, Tortosa, Prognostic factors for severity and mortality in patients infected with COVID-19: a systematic review, PLoS One, doi:10.1371/journal.pone.0241955
Klonoff, Messler, Umpierrez, Association between achieving inpatient glycemic control and clinical outcomes in hospitalized patients with COVID-19: a multicenter, retrospective hospital-based analysis, Diabetes Care, doi:10.2337/dc20-1857
Mehta, Kohn, Koliwad, Rushakoff, Lack of association between either outpatient or inpatient glycemic control and COVID-19 illness severity or mortality in patients with diabetes, BMJ Open Diabetes Res Care, doi:10.1136/bmjdrc-2021-002203
Mesas, Cavero-Redondo, Alvarez-Bueno, Predictors of in-hospital COVID-19 mortality: a comprehensive systematic review and meta-analysis exploring differences by age, sex and health conditions, PLoS One, doi:10.1371/journal.pone.0241742
Rosenthal, Cao, Gundrum, Sianis, Safo, Risk factors associated with in-hospital mortality in a US national sample of patients with COVID-19, JAMA Netw Open, doi:10.1001/jamanetworkopen.2020.29058
Wood, White, Royston, How should variable selection be performed with multiply imputed data?, Stat Med, doi:10.1002/sim.3177
Xian, Liu, Nilsson, Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation, Immunity, doi:10.1016/j.immuni.2021.05.004
Yan, Yang, Wang, Clinical characteristics and outcomes of patients with severe covid-19 with diabetes, BMJ Open Diabetes Research and Care, doi:10.1136/bmjdrc-2020-001343
Yang, Sun, Zhang, Zhang, The effect of metformin on mortality and severity in COVID-19 patients with diabetes mellitus, Diabetes Res Clin Pract, doi:10.1016/j.diabres.2021.108977
Zhu, She, Cheng, Association of blood glucose control and outcomes in patients with COVID-19 and preexisting type 2 diabetes, Cell Metabol, doi:10.1016/j.cmet.2020.04.021